Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35

•Desentralised plan comparison is robust; however, many aspects of treatment planning need to be validated.•Local plan comparison between protons and photons seems to overestimate the ΔNTCP slightly.•Target and OAR contouring differences play an important role in the robustness of the patient select...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiotherapy and oncology 2024-01, Vol.190, p.109812, Article 109812
Hauptverfasser: Hansen, Christian Rønn, Jensen, Kenneth, Smulders, Bob, Holm, Anne Ivalu Sander, Samsøe, Eva, Nielsen, Martin Skovmos, Sibolt, Patrik, Skyt, Peter, Elstrøm, Ulrik Vindelev, Nielsen, Camilla Panduro, Johansen, Jørgen, Zukauskaite, Ruta, Eriksen, Jesper Grau, Farhadi, Mohamma, Andersen, Maria, Andersen, Elo, Overgaard, Jens, Grau, Cai, Friborg, Jeppe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Desentralised plan comparison is robust; however, many aspects of treatment planning need to be validated.•Local plan comparison between protons and photons seems to overestimate the ΔNTCP slightly.•Target and OAR contouring differences play an important role in the robustness of the patient selection. Proton treatment can potentially spare patients with H&N cancer for substantial treatment-related toxicities. The current study investigated the reproducibility of a decentralised model-based selection of patients for a proton treatment study when the selection plans were compared to the clinical treatment plans performed at the proton centre. Sixty-three patients were selected for proton treatment in the six Danish Head and Neck Cancer (DAHANCA) centres. The patients were selected based on normal tissue complication probability (NTCP) estimated from local photon and proton treatment plans, which showed a ΔNTCP greater than 5%-point for either grade 2 + dysphagia or grade 2 + xerostomia at six months. The selection plans were compared to the clinical treatment plans performed at the proton centre. Of the 63 patients, 49 and 25 were selected based on an estimated benefit in risk of dysphagia and xerostomia, respectively. Eleven patients had a potential gain in both toxicities. The mean ΔNTCP changed from the local selection plan comparison to the clinical comparison from 6.9 to 5.3 %-points (p = 0.01) and 7.3 to 4.9 %-points (p = 0.03) for dysphagia and xerostomia, respectively. Volume differences in both CTV and OAR could add to the loss in ΔNTCP. 61 of the 63 clinical plans had a positive ΔNTCP, and 38 had a ΔNTCP of 5%-points for at least one of the two endpoints. A local treatment plan comparison can be used to select candidates for proton treatment. The local comparative proton plan overestimates the potential benefit of the clinical proton plan. Continuous quality assurance of the delineation procedures and planning is crucial in the subsequent randomised clinical trial setting.
ISSN:0167-8140
1879-0887
1879-0887
DOI:10.1016/j.radonc.2023.109812